Palo Alto, California, United States In 2001 was created Takeda Ventures, which is appeared as VC. The main office of represented VC is situated in the Palo Alto. The fund was located in North America if to be more exact in United States. Takeda Ventures seemed to be an CVC arrangement as part of the organization.
We also calculated 6 valuable employees in our database.
Among the most popular fund investment industries, there are Pharmaceutical, Health Care. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Obsidian Therapeutics, Juventas Therapeutics, BIOMx Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.
The fund is generally included in 2-6 deals every year. Comparing to the other companies, this Takeda Ventures performs on 13 percentage points less the average number of lead investments. The usual things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2017. The increased amount of exits for fund were in 2019. Speaking about the real fund results, this VC is 2 percentage points more often commits exit comparing to other organizations. The typical startup value when the investment from Takeda Ventures is 5-10 millions dollars.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Takeda Ventures, startups are often financed by Sofinnova Partners, Forbion Capital Partners, Novo Holdings. The meaningful sponsors for the fund in investment in the same round are Sofinnova Partners, Boehringer Ingelheim Venture Fund, SR One. In the next rounds fund is usually obtained by Sofinnova Partners, Savitr Capital, Providence Investment Company Limited.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Advance Newhouse | - |
| Alchemy Group | - |
| Armonia | Connecticut, Greenwich, United States |
| BBC Worldwide | England, London, United Kingdom |
| Carnegie Arch Capital | - |
| CCINT | China, Shanghai |
| Crown Castle | Houston, Texas, United States |
| Enterprise Development Corporation of South Florida | - |
| Goldwind | Beijing, Beijing, China |
| Imaginary Ventures | - |
| MITA Ventures | Jalisco, Mexico, Puerto Vallarta |
| National Capital Fund | Mazowieckie, Poland, Warszawa |
| Roca Junyent | Barcelona, Catalonia, Spain |
| SenseTime | Beijing, Beijing, China |
| Shenzhenshi Qianhai Hexiang Jijin | China, Guangdong, Shenzhen |
| SV Tech Ventures | California, Palo Alto, United States |
| The Oklahoman | Oklahoma, Oklahoma City, United States |
| TOKAI-SOFT | Japan, Shizuoka, Shizuoka Prefecture |
| True Blue Partners | - |
| Viaduct Ventures | California, Mountain View, United States |
Discover 4 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Larkspur Biosciences | $35M | 23 May 2023 | Watertown, Massachusetts, United States | ||
Cerevance | $51M | 13 Feb 2023 | Cambridge, Massachusetts, United States | ||
Ensoma | $85M | 05 Jan 2023 | Boston, Massachusetts, United States | ||
Enzyre | $14M | 02 Nov 2022 | Nijmegen, Gelderland, The Netherlands | ||
Code Biotherapeutics | $75M | 07 Jun 2022 | Hatfield, Pennsylvania, United States | ||
Be Biopharma | $130M | 14 Apr 2022 | Cambridge, Massachusetts, United States | ||
Koneksa Health | $45M | 07 Feb 2022 | New York, New York, United States | ||
Integra Therapeutics | $5M | 02 Dec 2021 | Barcelona, Catalonia, Spain | ||
Egle Therapeutics | $47M | 22 Oct 2021 | Paris, Ile-de-France, France |
– Turnstone Biologics Corp. announced the successful completion of an $80m Series D financing co-led by PFM Health Sciences and Point72.
– New investors include Eventide Asset Management, Surveyor Capital (a Citadel company), Ridgeback Capital Investments, Takeda Ventures, CaaS Capital, JM Family Enterprises, Inc., Northleaf Capital Partners, 404 Bio and an undisclosed investor.
– The round was joined by existing investors Versant Ventures, OrbiMed, F-Prime Capital, Sectoral Asset Management, Sixty Degree Capital, Brace Pharma Capital and Teralys Capital.
– Proceeds from the financing will be used to advance Turnstone’s pipeline of programs from its oncolytic virus and TIL therapy platforms.
– Ribon Therapeutics announced the closing of a $65m financing.
– The financing was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures, along with existing investors AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, Johnson & Johnson Innovation, Novartis Venture Fund, Osage University Partners, Takeda Ventures and The Column Group.
– Ribon will use the proceeds to support the clinical development of its novel precision medicine candidates.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Larkspur Biosciences | $35M | 23 May 2023 | Watertown, Massachusetts, United States | ||
Cerevance | $51M | 13 Feb 2023 | Cambridge, Massachusetts, United States | ||
Ensoma | $85M | 05 Jan 2023 | Boston, Massachusetts, United States | ||
Enzyre | $14M | 02 Nov 2022 | Nijmegen, Gelderland, The Netherlands | ||
Code Biotherapeutics | $75M | 07 Jun 2022 | Hatfield, Pennsylvania, United States | ||
Be Biopharma | $130M | 14 Apr 2022 | Cambridge, Massachusetts, United States | ||
Koneksa Health | $45M | 07 Feb 2022 | New York, New York, United States | ||
Integra Therapeutics | $5M | 02 Dec 2021 | Barcelona, Catalonia, Spain | ||
Egle Therapeutics | $47M | 22 Oct 2021 | Paris, Ile-de-France, France |
